share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024财年三季报
美股SEC公告 ·  2024/11/19 14:17

Moomoo AI 已提取核心信息

ENDRA Life Sciences reported financial results for Q3 2024, with net loss decreasing to $2.35 million compared to $3.10 million in Q3 2023. Research and development expenses declined 51% to $794,444, while sales and marketing expenses decreased 66% to $83,157, reflecting the company's transition from product development to commercialization focus.The company ended the quarter with $4.75 million in cash and working capital of $4.15 million. Management is pursuing additional financing options to support ongoing operations and commercialization plans, including potential sales of common stock through their at-the-market program. However, the company noted material concerns about its ability to continue as a going concern without securing adequate additional funding.ENDRA continues to advance its TAEUS technology platform, with plans to complete necessary clinical studies by Q4 2024 or Q1 2025 and submit a new de novo FDA request in H1 2025. The company has restructured its European sales operations and appointed Alexander Tokman as CEO and Chairman in August 2024 to lead its commercialization strategy.
ENDRA Life Sciences reported financial results for Q3 2024, with net loss decreasing to $2.35 million compared to $3.10 million in Q3 2023. Research and development expenses declined 51% to $794,444, while sales and marketing expenses decreased 66% to $83,157, reflecting the company's transition from product development to commercialization focus.The company ended the quarter with $4.75 million in cash and working capital of $4.15 million. Management is pursuing additional financing options to support ongoing operations and commercialization plans, including potential sales of common stock through their at-the-market program. However, the company noted material concerns about its ability to continue as a going concern without securing adequate additional funding.ENDRA continues to advance its TAEUS technology platform, with plans to complete necessary clinical studies by Q4 2024 or Q1 2025 and submit a new de novo FDA request in H1 2025. The company has restructured its European sales operations and appointed Alexander Tokman as CEO and Chairman in August 2024 to lead its commercialization strategy.
ENDRA Life Sciences公布了2024年第三季度的财务结果,净亏损减少至235万美元,相较于2023年第三季度的310万美元。研发支出下降51%,至794,444美元,而销售和市场费用下降66%,至83,157美元,这反映了公司从产品开发转向商业化的重点。公司在本季度末拥有475万美元的现金和415万美元的营运资金。管理层正在寻求额外的融资方案,以支持持续的运营和商业化计划,包括通过市场计划可能销售普通股。然而,公司指出,若未能获得足够的额外资金,将面临持续经营能力方面的重大担忧。ENDRA继续推进其TAEUS科技平台,计划在2024年第四季度或2025年第一季度完成必要的临床研究,并在2025年上半年提交新的de novo FDA申请。公司已重组其欧洲销售业务,并于2024年8月任命亚历山大·托克曼为首席执行官和董事长,以领导其商业化策略。
ENDRA Life Sciences公布了2024年第三季度的财务结果,净亏损减少至235万美元,相较于2023年第三季度的310万美元。研发支出下降51%,至794,444美元,而销售和市场费用下降66%,至83,157美元,这反映了公司从产品开发转向商业化的重点。公司在本季度末拥有475万美元的现金和415万美元的营运资金。管理层正在寻求额外的融资方案,以支持持续的运营和商业化计划,包括通过市场计划可能销售普通股。然而,公司指出,若未能获得足够的额外资金,将面临持续经营能力方面的重大担忧。ENDRA继续推进其TAEUS科技平台,计划在2024年第四季度或2025年第一季度完成必要的临床研究,并在2025年上半年提交新的de novo FDA申请。公司已重组其欧洲销售业务,并于2024年8月任命亚历山大·托克曼为首席执行官和董事长,以领导其商业化策略。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息